Secukinumab tames severe scalp psoriasis

 

VIENNA – Secukinumab proved highly effective specifically for the treatment of moderate to severe scalp psoriasis in a phase IIIb clinical trial, Mark G. Lebwohl, MD, reported at the annual congress of the European Academy of Dermatology and Venereology.

The scalp is one of the areas most commonly affected by psoriasis, yet few treatment trials have focused on patients with primarily moderate to severe scalp psoriasis. This phase IIIb study was designed to do just that. The 102 participants had psoriasis over a mean of 60% of their scalp for at least 6 months at baseline despite various forms of therapy; 40% had 70% or greater scalp involvement. The study population’s mean baseline Psoriasis Scalp Severity Index score was 34 out of a possible 72, noted Dr. Lebwohl, professor and chairman of the department of dermatology at the Icahn School of Medicine at Mount Sinai, New York.

Despite this florid scalp involvement, many subjects had only mild to moderate psoriasis at other sites. In this setting, a newer-generation potent biologic that’s been on the market long enough to have a well-established favorable safety profile – secukinumab was approved for psoriasis in January 2015 – is an attractive option.

“The mean involved body surface area was only 11.2%, and the PASI was 8.4. That is below the entry score required for most biologic studies, yet scalp involvement was substantial,” he observed.

Participants in the double-blind trial were randomized to either subcutaneous secukinumab (Cosentyx) at 300 mg on the approved treatment schedule for psoriasis or to placebo, with the primary endpoint being at least a 90% improvement in Psoriasis Area and Severity Index scores (PASI 90 response) at 12 weeks.

“The results were striking. Quite stunning,” Dr. Lebwohl said.

A PASI 90 response was achieved in 53% of secukinumab-treated patients, compared with 2% of controls. Already by week 3 a significant difference was apparent between the two study arms: At that early point, 12% of the secukinumab group, but none of the controls, had a PASI 90 response.

The secondary endpoint was change in the Investigator’s Global Assessment of scalp disease. At baseline, roughly 80% of patients had an IGA of 3 out of a possible 4 and the rest were at 4. At 3 weeks, 26% of the secukinumab group had a score of 0 or 1, signifying a clear or almost clear scalp, compared with 6% of controls. At 12 weeks, 57% of patients on secukinumab had an IGA of 0 or 1, as did 6% of those on placebo.

Side effects of secukinumab in the 12-week study were minimal. There were no serious adverse events. One case of candidiasis occurred in each study arm. Both responded readily to standard therapy.

Secukinumab is a fully human monoclonal antibody that inhibits interleukin-17A. It’s approved for treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis.

This phase IIIb clinical trial was sponsored by Novartis. Dr. Lebwohl reported that his department receives research funding from Novartis and roughly a dozen other pharmaceutical companies.

[email protected]

 

VIENNA – Secukinumab proved highly effective specifically for the treatment of moderate to severe scalp psoriasis in a phase IIIb clinical trial, Mark G. Lebwohl, MD, reported at the annual congress of the European Academy of Dermatology and Venereology.

The scalp is one of the areas most commonly affected by psoriasis, yet few treatment trials have focused on patients with primarily moderate to severe scalp psoriasis. This phase IIIb study was designed to do just that. The 102 participants had psoriasis over a mean of 60% of their scalp for at least 6 months at baseline despite various forms of therapy; 40% had 70% or greater scalp involvement. The study population’s mean baseline Psoriasis Scalp Severity Index score was 34 out of a possible 72, noted Dr. Lebwohl, professor and chairman of the department of dermatology at the Icahn School of Medicine at Mount Sinai, New York.

Despite this florid scalp involvement, many subjects had only mild to moderate psoriasis at other sites. In this setting, a newer-generation potent biologic that’s been on the market long enough to have a well-established favorable safety profile – secukinumab was approved for psoriasis in January 2015 – is an attractive option.

“The mean involved body surface area was only 11.2%, and the PASI was 8.4. That is below the entry score required for most biologic studies, yet scalp involvement was substantial,” he observed.

Participants in the double-blind trial were randomized to either subcutaneous secukinumab (Cosentyx) at 300 mg on the approved treatment schedule for psoriasis or to placebo, with the primary endpoint being at least a 90% improvement in Psoriasis Area and Severity Index scores (PASI 90 response) at 12 weeks.

“The results were striking. Quite stunning,” Dr. Lebwohl said.

A PASI 90 response was achieved in 53% of secukinumab-treated patients, compared with 2% of controls. Already by week 3 a significant difference was apparent between the two study arms: At that early point, 12% of the secukinumab group, but none of the controls, had a PASI 90 response.

The secondary endpoint was change in the Investigator’s Global Assessment of scalp disease. At baseline, roughly 80% of patients had an IGA of 3 out of a possible 4 and the rest were at 4. At 3 weeks, 26% of the secukinumab group had a score of 0 or 1, signifying a clear or almost clear scalp, compared with 6% of controls. At 12 weeks, 57% of patients on secukinumab had an IGA of 0 or 1, as did 6% of those on placebo.

Side effects of secukinumab in the 12-week study were minimal. There were no serious adverse events. One case of candidiasis occurred in each study arm. Both responded readily to standard therapy.

Secukinumab is a fully human monoclonal antibody that inhibits interleukin-17A. It’s approved for treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis.

This phase IIIb clinical trial was sponsored by Novartis. Dr. Lebwohl reported that his department receives research funding from Novartis and roughly a dozen other pharmaceutical companies.

[email protected]

 

VIENNA – Secukinumab proved highly effective specifically for the treatment of moderate to severe scalp psoriasis in a phase IIIb clinical trial, Mark G. Lebwohl, MD, reported at the annual congress of the European Academy of Dermatology and Venereology.

The scalp is one of the areas most commonly affected by psoriasis, yet few treatment trials have focused on patients with primarily moderate to severe scalp psoriasis. This phase IIIb study was designed to do just that. The 102 participants had psoriasis over a mean of 60% of their scalp for at least 6 months at baseline despite various forms of therapy; 40% had 70% or greater scalp involvement. The study population’s mean baseline Psoriasis Scalp Severity Index score was 34 out of a possible 72, noted Dr. Lebwohl, professor and chairman of the department of dermatology at the Icahn School of Medicine at Mount Sinai, New York.

Despite this florid scalp involvement, many subjects had only mild to moderate psoriasis at other sites. In this setting, a newer-generation potent biologic that’s been on the market long enough to have a well-established favorable safety profile – secukinumab was approved for psoriasis in January 2015 – is an attractive option.

“The mean involved body surface area was only 11.2%, and the PASI was 8.4. That is below the entry score required for most biologic studies, yet scalp involvement was substantial,” he observed.

Participants in the double-blind trial were randomized to either subcutaneous secukinumab (Cosentyx) at 300 mg on the approved treatment schedule for psoriasis or to placebo, with the primary endpoint being at least a 90% improvement in Psoriasis Area and Severity Index scores (PASI 90 response) at 12 weeks.

“The results were striking. Quite stunning,” Dr. Lebwohl said.

A PASI 90 response was achieved in 53% of secukinumab-treated patients, compared with 2% of controls. Already by week 3 a significant difference was apparent between the two study arms: At that early point, 12% of the secukinumab group, but none of the controls, had a PASI 90 response.

The secondary endpoint was change in the Investigator’s Global Assessment of scalp disease. At baseline, roughly 80% of patients had an IGA of 3 out of a possible 4 and the rest were at 4. At 3 weeks, 26% of the secukinumab group had a score of 0 or 1, signifying a clear or almost clear scalp, compared with 6% of controls. At 12 weeks, 57% of patients on secukinumab had an IGA of 0 or 1, as did 6% of those on placebo.

Side effects of secukinumab in the 12-week study were minimal. There were no serious adverse events. One case of candidiasis occurred in each study arm. Both responded readily to standard therapy.

Secukinumab is a fully human monoclonal antibody that inhibits interleukin-17A. It’s approved for treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis.

This phase IIIb clinical trial was sponsored by Novartis. Dr. Lebwohl reported that his department receives research funding from Novartis and roughly a dozen other pharmaceutical companies.

[email protected]